Laboratory aspects of von Willebrand disease: test repertoire and options for activity assays and genetic analysis

被引:22
作者
Castaman, G. [1 ]
Hillarp, A. [2 ]
Goodeve, A. [3 ,4 ]
机构
[1] San Bartolo Hosp, Dept Cell Therapy & Hematol, Hemophilia & Thrombosis Ctr, Vicenza, Italy
[2] Skane Univ Hosp, Dept Clin Chem, Malmo Ctr Thrombosis & Haemostasis, SE-20502 Malmo, Sweden
[3] Univ Sheffield, Dept Cardiovasc Sci, Sheffield Childrens NHS Fdn Trust, Sheffield Diagnost Genet Serv, Sheffield, S Yorkshire, England
[4] Univ Sheffield, Dept Cardiovasc Sci, Haemostasis Res Grp, Sheffield, S Yorkshire, England
关键词
von Willebrand disease; ristocetin cofactor; laboratory diagnosis; genetic testing; von Willebrand factor activity; BLEEDING SYMPTOMS; DIAGNOSIS; VWF; IDENTIFICATION; MUTATIONS; DOMAIN; COHORT;
D O I
10.1111/hae.12410
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The deficiency or abnormal function of von Willebrand factor (VWF) causes von Willebrand disease (VWD), the most frequent inherited bleeding disorder. The laboratory diagnosis of VWD can be difficult as the disease is heterogeneous and an array of assays is required to describe the phenotype. Basic classification of quantitative (type 1 and 3) and qualitative (type 2) VWD variants requires determination of VWF antigenic (VWF:Ag) levels and assaying of VWF ristocetin cofactor (VWF:RCo) activity, determining the capacity of VWF to interact with the platelet GPIb-receptor. Knowing the VWF:RCo activity is essential for identifying, subtyping and monitoring VWD, but the assay is poorly standardized and many protocols do not fulfil the clinical need in all situations. This has led to the development of novel activity assays, independent of ristocetin, with enhanced assay characteristics. Results from the first independent clinical evaluations are promising, showing that they are reliable and suitable for VWD diagnosis. The qualitative type 2 VWF deficiency can be further divided into four different subtypes (A, B, M and N) using specific assays that explore other activities or the size distribution of VWF multimers. These methods are discussed herein. However, in a number of patients it may be difficult to correctly classify the VWD phenotype and genetic analysis may provide the best option to clarify the disorder, through mutation identification.
引用
收藏
页码:65 / 70
页数:6
相关论文
共 30 条
[1]  
[Anonymous], PRACTICE GUIDELINES
[2]  
[Anonymous], PRACTICAL HEMOSTASIS
[3]   Detection of VWF Copy Number Variations by Microarray Analysis in Von Willebrand Disease Type 3 Index Cases [J].
Bellissimo, Daniel B. ;
Chin, Ephrem ;
Hegde, Madhuri ;
Christopherson, Pamela A. ;
Haberichter, Sandra L. ;
Montgomery, Robert R. .
BLOOD, 2011, 118 (21) :175-176
[4]   Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire [J].
Biss, T. T. ;
Blanchette, V. S. ;
Clark, D. S. ;
Bowman, M. ;
Wakefield, C. D. ;
Silva, M. ;
Lillicrap, D. ;
James, P. D. ;
Rand, M. L. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (05) :950-956
[5]   The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles [J].
Bowman, M. ;
Tuttle, A. ;
Notley, C. ;
Brown, C. ;
Tinlin, S. ;
Deforest, M. ;
Leggo, J. ;
Blanchette, V. S. ;
Lillicrap, D. ;
James, P. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (03) :512-520
[6]   Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method [J].
Cabrera, N. ;
Moret, A. ;
Caunedo, P. ;
Cid, A. R. ;
Vila, V. ;
Espana, F. ;
Aznar, J. A. .
HAEMOPHILIA, 2013, 19 (06) :920-925
[7]   First application of MLPA method in severe von Willebrand disease. Confirmation of a new large VWF gene deletion and identification of heterozygous carriers [J].
Cabrera, Noelia ;
Casana, Pilar ;
Cid, Ana Rosa ;
Moret, Andres ;
Moreno, Manuel ;
Palomo, Angeles ;
Antonio Aznar, Jose .
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (02) :240-242
[8]   Principles of care for the diagnosis and treatment of von Willebrand disease [J].
Castaman, Giancarlo ;
Goodeve, Anne ;
Eikenboom, Jeroen .
HAEMATOLOGICA, 2013, 98 (05) :667-674
[9]   von Willebrand Factor Assay Proficiency Testing The North American Specialized Coagulation Laboratory Association Experience [J].
Chandler, Wayne L. ;
Peerschke, Ellinor I. B. ;
Castellone, Donna D. ;
Meijer, Piet .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2011, 135 (06) :862-869
[10]   VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease [J].
Eikenboom, Jeroen ;
Federici, Augusto B. ;
Dirven, Richard J. ;
Castaman, Giancarlo ;
Rodeghiero, Francesco ;
Budde, Ulrich ;
Schneppenheim, Reinhard ;
Batlle, Javier ;
Canciani, Maria Teresa ;
Goudemand, Jenny ;
Peake, Ian ;
Goodeve, Anne .
BLOOD, 2013, 121 (12) :2336-2339